# Plasma Dosage of Venetoclax in the Fup of AML Patients Treated With Aza + Ven

> **NCT06030089** · NA · COMPLETED · sponsor: **Centre Hospitalier Universitaire de Nice** · enrollment: 20 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **OTHER:** Pharmacokinetic sampling
- **OTHER:** Vital status determination
- **OTHER:** Toxicity assessments
- **DRUG:** Venetoclax and azacitidine combination

## Key facts

- **NCT ID:** NCT06030089
- **Lead sponsor:** Centre Hospitalier Universitaire de Nice
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-02-26
- **Primary completion:** 2024-09-30
- **Final completion:** 2025-03-03
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06030089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06030089, "Plasma Dosage of Venetoclax in the Fup of AML Patients Treated With Aza + Ven". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT06030089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*